Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria

Rena Baek, Kimberly Coughlan, Lei Jiang, Min Liang, Lei Ci, Harkewal Singh, Hannah Zhang, Neeraj Kaushal, Ivana Liric Rajlic, Linh Van, Rain Dimen, Alexander Cavedon, Ling Yin, Lisa Rice, Andrea Frassetto, Lin Guey (), Patrick Finn () and Paolo G. V. Martini ()
Additional contact information
Rena Baek: Inc.
Kimberly Coughlan: Inc.
Lei Jiang: Inc.
Min Liang: Inc.
Lei Ci: Inc.
Harkewal Singh: Inc.
Hannah Zhang: Inc.
Neeraj Kaushal: Inc.
Ivana Liric Rajlic: Inc.
Linh Van: Inc.
Rain Dimen: Inc.
Alexander Cavedon: Inc.
Ling Yin: Inc.
Lisa Rice: Inc.
Andrea Frassetto: Inc.
Lin Guey: Inc.
Patrick Finn: Inc.
Paolo G. V. Martini: Inc.

Nature Communications, 2024, vol. 15, issue 1, 1-13

Abstract: Abstract Messenger RNA (mRNA) therapeutics delivered via lipid nanoparticles hold the potential to treat metabolic diseases caused by protein deficiency, including propionic acidemia (PA), methylmalonic acidemia (MMA), and phenylketonuria (PKU). Herein we report results from multiple independent preclinical studies of mRNA-3927 (an investigational treatment for PA), mRNA-3705 (an investigational treatment for MMA), and mRNA-3210 (an investigational treatment for PKU) in murine models of each disease. All 3 mRNA therapeutics exhibited pharmacokinetic/pharmacodynamic (PK/PD) responses in their respective murine model by driving mRNA, protein, and/or protein activity responses, as well as by decreasing levels of the relevant biomarker(s) when compared to control-treated animals. These preclinical data were then used to develop translational PK/PD models, which were scaled allometrically to humans to predict starting doses for first-in-human clinical studies for each disease. The predicted first-in-human doses for mRNA-3927, mRNA-3705, and mRNA-3210 were determined to be 0.3, 0.1, and 0.4 mg/kg, respectively.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-47460-9 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-47460-9

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-47460-9

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().